Ki-67 index as a prognostic factor of subsequent lapatinib-based therapy in HER2-positive metastatic breast cancer with resistance to trastuzumab

Cancer Biology and Therapy

Volumn 15, Issue 4, 2014, Pages 365-370

  Bian, Li ^a   Wang, Tao ^a   Zhang, Shao Hua ^a   Zhang, Hui Qiang ^a   Guo, Yun Fei ^a   Du, Ge ^a   Li, Wang ^a   Wu, Shi Kai ^a   Song, San Tai ^a   Jiang, Ze Fei ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

HER2 positive; Ki 67; Lapatinib; Metastatic breast cancer; Prognostic factor; Resistance; Trastuzumab

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; LAPATINIB; PROTEIN P53; TRASTUZUMAB; TUMOR MARKER; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

ADULT; AGE; ARTICLE; BRAIN METASTASIS; BREAST BIOPSY; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CLINICAL EVALUATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; ADOLESCENT; AGED; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; DRUG RESISTANCE; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; QUINAZOLINES; RECEPTOR, ERBB-2; TRASTUZUMAB; YOUNG ADULT;

EID: 84897561243     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.27624     Document Type: Article

References (21)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-82; PMID:3798106; http://dx.doi.org/ 10.1126/science.3798106
2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92; PMID:11248153; http://dx.doi.org/10.1056/ NEJM200103153441101
3. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23:4265-74; PMID:15911866; http://dx.doi.org/10.1200/JCO.2005.04.173
4. Schaller G, Fuchs I, Gonsch T, Weber J, Kleine-Tebbe A, Klare P, Hindenburg HJ, Lakner V, Hinke A, Bangemann N. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol 2007; 25:3246-50; PMID:17577021; http://dx.doi.org/10.1200/JCO.2006.09.6826
5. Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 2008; 30:1426-47; PMID:18803986; http://dx.doi.org/10.1016/j.clinthera.2008.08.008
6. Tevaarwerk AJ, Kolesar JM. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther 2009; 31:2332-48; PMID:20110044; http://dx.doi.org/10.1016/j.clinthera.2009.11.029
7. Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 2007; 6:667-74; PMID:17308062; http://dx.doi.org/10.1158/1535-7163.MCT-06-0423
8. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355:2733- 43; PMID:17192538; http://dx.doi.org/10.1056/NEJMoa064320
9. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112:533-43; PMID:18188694; http://dx.doi.org/10.1007/s10549-007-9885-0
10. Capri G, Chang J, Chen SC, Conte P, Cwiertka K, Jerusalem G, Jiang Z, Johnston S, Kaufman B, Link J, et al. An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol 2010; 21:474-80; PMID:19815649; http://dx.doi.org/10.1093/annonc/mdp373
11. Xu BH, Jiang ZF, Chua D, Shao ZM, Luo RC, Wang XJ, Liu DG, Yeo W, Yu SY, Newstat B, et al. Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. Chin J Cancer 2011; 30:327-35; PMID:21527065; http://dx.doi.org/10.5732/cjc.010. 10507
12. Kostyal D, Welt RS, Danko J, Shay T, Lanning C, Horton K, Welt S. Trastuzumab and lapatinib modulation of HER2 tyrosine/threonine phosphorylation and cell signaling. Med Oncol 2012; 29:1486-94; PMID:21769502; http://dx.doi.org/10.1007/s12032-011-0025-7
13. Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 2010; 15:924-34; PMID:20736298; http://dx.doi.org/10.1634/theoncologist.2009-0181
14. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010; 11:174-83; PMID:20152769; http://dx.doi.org/10.1016/S1470-2045(09)70262-1
15. Ben-Izhak O, Bar-Chana M, Sussman L, Dobiner V, Sandbank J, Cagnano M, Cohen H, Sabo E. Ki67 antigen and PCNA proliferation markers predict survival in anorectal malignant melanoma. Histopathology 2002; 41:519-25; PMID:12460204; http://dx.doi.org/10.1046/j.1365-2559.2002.01444.x
16. Salminen E, Palmu S, Vahlberg T, Roberts PJ, Söderström KO. Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer. World J Gastroenterol 2005; 11:3245-9; PMID:15929175
17. Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med 2010; 1:747-54; PMID:22993598; http://dx.doi.org/10.3892/etm.2010.133
18. Bianchini G, Gianni L. Surrogate markers for targeted therapy-based treatment activity and efficacy. J Natl Cancer Inst Monogr 2011; 2011:91-4; PMID:22043050; http://dx.doi.org/10.1093/jncimonographs/lgr024
19. Dowsett M, Smith I, Robertson J, Robison L, Pinhel I, Johnson L, Salter J, Dunbier A, Anderson H, Ghazoui Z, et al. Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. J Natl Cancer Inst Monogr 2011; 2011:120-3; PMID:22043057; http://dx.doi.org/10.1093/ jncimonographs/lgr034
20. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6:117-27; PMID:15324695; http://dx.doi.org/10.1016/j.ccr.2004. 06.022
21. Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med 2010; 1:747-54; PMID:22993598; http://dx.doi.org/10.3892/etm.2010.133